Gilead quarterly revenue drops 4%, oral COVID drug fails trial

By Deena Beasley (Reuters) -Gilead Sciences on Tuesday said fourth-quarter revenue dipped 4% on lower sales of HIV drugs and its infused COVID-19 treatment ...

Related Keywords

New Jersey ,United States ,California ,Los Angeles ,Sonali Paul ,Merdad Parsey ,Michael Yee ,Deena Beasley ,Reuters ,Gilead Sciences On ,Gilead Sciences ,Chief Medical Officer Merdad Parsey ,Wall Street ,Reporting By Deena Beasley ,Michael Erman ,Bill Berkrot ,